Ignite Creation Date:
2024-05-06 @ 8:17 PM
Last Modification Date:
2024-10-26 @ 3:24 PM
Study NCT ID:
NCT06323161
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-03-15
Brief Title:
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin
Sponsor:
Novo Nordisk AS
Organization:
Novo Nordisk AS
Study Overview
Official Title:
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide CagriSema sc in Doses 24 mg24 mg and 10 mg10 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes as Add on to Once-daily Basal Insulin With or Without Metformin
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REIMAGINE 3
Brief Summary:
This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight CagriSema is a new investigational medicine Doctors may not yet prescribe CagriSema CagriSema will be compared to a dummy medicine also called placebo that has no effect on the body Participant will get either CagriSema or dummy medicine and which treatment they get is decided by chance Participant will take the study medicine together with their current diabetes medicine once-daily insulin with or without metformin For each participant the study will last for about one year
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2022-502679-43 | OTHER | European Medical Agency EMA | None |
| U1111-1283-0754 | OTHER | None | None |